Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GSK2636771 + Enzalutamide in PTEN-deficient mCRPC
NCT02215096Phase 1Completed
- Sponsor
- GSK
- Start
- Nov 2014
- Primary completion
- Oct 2019
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, Orthosteric Ligands
- Countries
- 2
01
Overview
Phase 1, open-label trial of GSK-2636771 in metastatic castration-resistant prostate cancer (mCRPC) (2 arms), sponsored by GSK. Primary endpoints: Number of Participants With Non-serious Adverse Events (Non-SAEs) and Serious Adverse Events (SAEs), Number of Participant With Dose-limiting Toxicities (DLT) and 7 more. Started Nov 2014; status: completed.
02
Drugs
GSK-2636771
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT02215096.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02215096.